Comprehensive Botulinum Characterization via the Bilayer Nanowell Integrated Assay

项目总结

Project Summary During this program, Electronic BioSciences, Inc. (EBS) will develop and validate its in-vitro, chip-based, picowell bilayer integrated assay (BP-IA) for characterizing the complete activity of botulinum toxin serotype A (BoNT/A) transmembrane toxin. A transmembrane toxin is a molecule that recognizes/targets a specific cell type via receptor-mediated targeting/endocytosis, forms a pore in the cell membrane, and transports itself or another molecule into the cell to disrupt cellular function, e.g., botulinum neurotoxin, tetanus, diphtheria, shiga, cholera, pertussis, etc. While these toxins are innately hazardous to human health, their inherent cell targeting and enzymatic capabilities can also be harnessed for therapeutic benefit. Today, the emerging therapeutic uses of toxins include but are not limited to the treatment of muscle spasms, wrinkles, excessive sweating, depression, anxiety, anorexia, neurodegenerative disorders (e.g., Parkinson’s disease), and targeted cancer therapy. However, the limitations of current toxin activity assessment methods have constrained the field. There is a need for a low cost, easy-to-use, rapid, highly sensitive, highly reproducible assay that is capable of individually quantifying the separate steps of the intoxication mechanism (i.e., the cell targeting/endocytosis and the intracellular enzymatic activity) to fully understand and utilize toxin functionality. The present standard for toxin activity assessments is the mouse intraperitoneal injection assay, which has numerous limitations, including price, variability, time, lack of sample quantification, and the utilization of live animals, in addition relying on a single endpoint determination that precludes assessment of the toxin’s mechanism. Unknown or poorly understood differences in the potency (or mode of action) of toxin-containing therapeutics can confound clinical dose findings, result in over or under dosing patients, and delay (or prohibit) the development and/or availability of new/novel therapeutics. EBS’ BP-IA technology will be capable of unprecedented toxin characterization in a low cost, easy-to-use, rapid, highly sensitive, highly reproducible, in vitro, chip-based platform. Furthermore, the methodology of the BP-IA is customizable such that the complete activity of any transmembrane toxin could be quantified. The development of the BP-IA under this Phase I program will be accomplished by developing and building an alpha prototype BP-IA device, and demonstrating the capability of the BP-IA device to quantitatively assess the potency of commercial BoNT/A therapeutic toxin formulations. Development of the BP-IA, a technology for which there is no equivalent commercially available and the future gold standard in toxin, biotherapeutics, cell-targeting, uptake/internal activity, and causation mechanism quantification, will directly enable the research and development of BoNT/A-based therapeutics, novel toxin agents/samples, the development of antitoxin agents, the detailed study of toxin and antitoxin mechanisms, the evaluation of the causative effects of experimental variables on each specific intoxication modality, and the assessment of toxin potency in general.